Sotyktu Alternatives Compared
| Sotyktu (deucravacitinib) | Otezla (apremilast) | Skyrizi (risankizumab) |
|
|---|
| Sotyktu (deucravacitinib) | Otezla (apremilast) | Skyrizi (risankizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Plaque Psoriasis. Sotyktu may also be used for purposes not listed in this medication guide. |
Prescription only
Otezla is a PDE4 inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease. It may also be used to treat plaque psoriasis... View more |
Prescription only
Skyrizi is an interleukin inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis (UC). The usual dosage is 150mg every 12 weeks... View more |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
| More about Sotyktu (deucravacitinib) | More about Otezla (apremilast) | More about Skyrizi (risankizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Sotyktu has an average rating of 6.6 out of 10 from a total of 13 ratings on Drugs.com. 54% of reviewers reported a positive effect, while 23% reported a negative effect. |
Otezla has an average rating of 5.2 out of 10 from a total of 440 ratings on Drugs.com. 35% of reviewers reported a positive effect, while 40% reported a negative effect. |
Skyrizi has an average rating of 8.0 out of 10 from a total of 57 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 14% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Sotyktu side effects |
View all Otezla side effects |
View all Skyrizi side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Sotyktu prices |
View all Otezla prices |
View all Skyrizi prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
10 hours |
9 hours |
672 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 472 drugs are known to interact with Sotyktu:
|
A total of 108 drugs are known to interact with Otezla:
|
A total of 185 drugs are known to interact with Skyrizi:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
September 09, 2022 |
March 21, 2014 |
April 23, 2019 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.